Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 17/20 | 0.69 |
| ▸ | CNR2 | P34972 | 10/20 | 0.66 |
| ▸ | ALPL | P05186 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3362851 | 0.86 | CNR1 (0.65) | CNR1CNR2L3MBTL1POLB | |
| SCHEMBL3369694 | 0.86 | CNR1 (0.65) | CNR1CNR2L3MBTL1POLB | |
| SCHEMBL3364881 | 0.84 | CNR1 (0.60) | CNR1CNR2L3MBTL1POLB | |
| SCHEMBL3629336 | 0.82 | CNR1 (0.66) | CNR1CNR2ALPL | |
| SCHEMBL3367684 | 0.82 | CNR1 (0.65) | CNR1CNR2 | |
| SCHEMBL3366114 | 0.82 | CNR1 (0.65) | CNR1CNR2 | |
| SCHEMBL5094249 | 0.81 | CNR1 (0.62) | CNR1CNR2L3MBTL1POLB | |
| SCHEMBL3367034 | 0.80 | CNR1 (0.63) | CNR1CNR2 | |
| Hydrochloric Acid SCHEMBL3363172 | 0.79 | CNR1 (0.98) | CNR1CNR2 | |
| SCHEMBL674361 | 0.79 | CNR1 (1.00) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542678-B1 | 1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE DERIVATIVES AS CANNABINOID-CB sb 1 /sb RECEPTOR LIGANDS | SOLVAY PHARM BV (NL) | 2010-02-24 | — | — | EP | disclosed |
| US-7319110-B2 | 1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-01-15 | — | — | US | disclosed |
| EP-1753413-A2 | NOVEL MEDICAL USES OF COMPOUNDS SHOWING CB SB 1/SB -ANTAGONISTIC ACTIVITY AND COMBINATION TREATMENT INVOLVING SAID COMPOUNDS | Solvay Pharmaceuticals GmbH (DE) | 2007-02-21 | — | — | EP | disclosed |
| EP-1542678-A1 | 1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE DERIVATIVES AS CANNABINOID-CB sb 1 /sb RECEPTOR LIGANDS | Solvay Pharmaceuticals B.V. (NL) | 2005-06-22 | — | — | EP | disclosed |
| US-20050124660-A1 | Compounds for treatment of diseases using enzyme inhibitors, cognition activators for nervous system disorders, psychological disorders or obesity in children | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-06-09 | — | — | US | disclosed |
| WO-2005039550-A2 | NOVEL MEDICAL USES OF COMPOUNDS SHOWING CB1-ANTAGONISTIC ACTIVITY AND COMBINATION TREATMENT INVOLVING SAID COMPOUNDS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-05-06 | — | — | WO | disclosed |
| US-20040106614-A1 | 1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2004-06-03 | — | — | US | disclosed |
| WO-2004026301-A1 | 1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE DERIVATIVES AS CANNABINOID-CB1 RECEPTOR LIGANDS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106614-A1 | 1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity | CNR1, CNR2, GPR3 | CNR1 1/4885CNR2 2/4885ALPL 4457/4885 |
| US-20050124660-A1 | Compounds for treatment of diseases using enzyme inhibitors, cognition activators for nervous system disorders, psychological disorders or obesity in children | PNLIP, DLAT, LPCAT3 | CNR1 46/4885CNR2 28/4885ALPL 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.